Profitability
This table compares Interpace Biosciences and Biotricity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Interpace Biosciences | 65.25% | 219.07% | 105.05% |
| Biotricity | -80.42% | N/A | -188.47% |
Institutional and Insider Ownership
5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Interpace Biosciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Interpace Biosciences | $38.73 million | 0.21 | $24.58 million | ($0.05) | -36.40 |
| Biotricity | $12.06 million | 0.28 | -$14.09 million | ($0.16) | -0.75 |
Interpace Biosciences has higher revenue and earnings than Biotricity. Interpace Biosciences is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.
Summary
Interpace Biosciences beats Biotricity on 7 of the 11 factors compared between the two stocks.
About Interpace Biosciences
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
